MX2021004452A - Esteroides neuroactivos no saturados 9(11) y sus métodos de uso. - Google Patents
Esteroides neuroactivos no saturados 9(11) y sus métodos de uso.Info
- Publication number
- MX2021004452A MX2021004452A MX2021004452A MX2021004452A MX2021004452A MX 2021004452 A MX2021004452 A MX 2021004452A MX 2021004452 A MX2021004452 A MX 2021004452A MX 2021004452 A MX2021004452 A MX 2021004452A MX 2021004452 A MX2021004452 A MX 2021004452A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- unsaturated
- neuroactive steroids
- compound
- formula
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0007—Androstane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748016P | 2018-10-19 | 2018-10-19 | |
| PCT/US2019/057195 WO2020082065A1 (en) | 2018-10-19 | 2019-10-21 | 9(11)-unsaturated neuroactive steroids and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021004452A true MX2021004452A (es) | 2021-08-11 |
Family
ID=68468867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021004452A MX2021004452A (es) | 2018-10-19 | 2019-10-21 | Esteroides neuroactivos no saturados 9(11) y sus métodos de uso. |
| MX2024014845A MX2024014845A (es) | 2018-10-19 | 2021-04-16 | Esteroides neuroactivos no saturados 9(11) y sus metodos de uso |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024014845A MX2024014845A (es) | 2018-10-19 | 2021-04-16 | Esteroides neuroactivos no saturados 9(11) y sus metodos de uso |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20210363175A1 (https=) |
| EP (2) | EP3867261B1 (https=) |
| JP (2) | JP7534291B2 (https=) |
| CN (1) | CN113227114B (https=) |
| AR (1) | AR116771A1 (https=) |
| AU (2) | AU2019359899B2 (https=) |
| BR (1) | BR112021007401A2 (https=) |
| CA (1) | CA3116892A1 (https=) |
| DK (1) | DK3867261T3 (https=) |
| ES (1) | ES3039267T3 (https=) |
| MX (2) | MX2021004452A (https=) |
| TW (1) | TW202027754A (https=) |
| WO (1) | WO2020082065A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2806877B2 (en) | 2012-01-23 | 2025-01-29 | Sage Therapeutics, Inc. | Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| KR102396328B1 (ko) | 2013-04-17 | 2022-05-10 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3504189A1 (en) | 2016-08-23 | 2019-07-03 | Sage Therapeutics, Inc. | A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid |
| MA51046A (fr) | 2017-12-08 | 2021-03-17 | Sage Therapeutics Inc | Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| DE2526373C2 (de) * | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| EP0221705A1 (en) * | 1985-10-23 | 1987-05-13 | The Upjohn Company | Tetrahydro angiostatic steroids |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| CN117024501A (zh) * | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
-
2019
- 2019-10-21 ES ES19798489T patent/ES3039267T3/es active Active
- 2019-10-21 WO PCT/US2019/057195 patent/WO2020082065A1/en not_active Ceased
- 2019-10-21 EP EP19798489.1A patent/EP3867261B1/en active Active
- 2019-10-21 TW TW108137951A patent/TW202027754A/zh unknown
- 2019-10-21 JP JP2021521085A patent/JP7534291B2/ja active Active
- 2019-10-21 AU AU2019359899A patent/AU2019359899B2/en active Active
- 2019-10-21 AR ARP190102988A patent/AR116771A1/es unknown
- 2019-10-21 US US17/286,524 patent/US20210363175A1/en not_active Abandoned
- 2019-10-21 CA CA3116892A patent/CA3116892A1/en active Pending
- 2019-10-21 CN CN201980083218.9A patent/CN113227114B/zh active Active
- 2019-10-21 BR BR112021007401-5A patent/BR112021007401A2/pt unknown
- 2019-10-21 MX MX2021004452A patent/MX2021004452A/es unknown
- 2019-10-21 EP EP25172672.5A patent/EP4606812A3/en active Pending
- 2019-10-21 DK DK19798489.1T patent/DK3867261T3/da active
-
2021
- 2021-04-16 MX MX2024014845A patent/MX2024014845A/es unknown
-
2024
- 2024-05-07 JP JP2024075254A patent/JP2024096347A/ja active Pending
- 2024-09-30 AU AU2024220209A patent/AU2024220209A1/en active Pending
- 2024-11-07 US US18/940,062 patent/US20250136638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4606812A3 (en) | 2025-10-15 |
| WO2020082065A1 (en) | 2020-04-23 |
| EP3867261B1 (en) | 2025-04-30 |
| JP2024096347A (ja) | 2024-07-12 |
| EP3867261A1 (en) | 2021-08-25 |
| TW202027754A (zh) | 2020-08-01 |
| US20210363175A1 (en) | 2021-11-25 |
| EP4606812A2 (en) | 2025-08-27 |
| US20250136638A1 (en) | 2025-05-01 |
| CN113227114B (zh) | 2026-01-27 |
| DK3867261T3 (da) | 2025-08-18 |
| AR116771A1 (es) | 2021-06-09 |
| ES3039267T3 (en) | 2025-10-20 |
| AU2024220209A1 (en) | 2024-10-17 |
| AU2019359899B2 (en) | 2024-07-04 |
| CN113227114A (zh) | 2021-08-06 |
| AU2019359899A1 (en) | 2021-05-20 |
| MX2024014845A (es) | 2025-01-09 |
| JP2022505146A (ja) | 2022-01-14 |
| JP7534291B2 (ja) | 2024-08-14 |
| CA3116892A1 (en) | 2020-04-23 |
| BR112021007401A2 (pt) | 2021-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004452A (es) | Esteroides neuroactivos no saturados 9(11) y sus métodos de uso. | |
| SA521430928B1 (ar) | ستيرويدات نشطة عصبيًا وتركيبات منها | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| MX2021006618A (es) | Esteroides neuroactivos y sus metodos de uso. | |
| PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| MX2022016230A (es) | Clorhidrato de (s)-(4,5-dihidro-7h-tieno[2,3-c]piran-7-il)-nmetilm etanamina cristalino y formulaciones de las mismas. | |
| WO2008133273A1 (ja) | アルツハイマー症治療用医薬組成物 | |
| EA038122B9 (ru) | Ингибитор поверхностного антигена вируса гепатита b | |
| NZ599344A (en) | Formulations comprising triptan compounds | |
| MX2021004159A (es) | Esteroides neuroactivos sustituidos en la posicion 10 con un grupo ciclico para uso en el tratamiento de trastornos del snc. | |
| MXPA05014163A (es) | Metodos y dispositivos para el tratamiento de lesiones cutaneas. | |
| SG10201903619YA (en) | Carbazole derivatives | |
| MX2025000126A (es) | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos | |
| DE602004021959D1 (de) | Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor | |
| MX2017007814A (es) | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| PH12021553056A1 (en) | Modified release formulations and uses thereof | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| PE20191240A1 (es) | Formas de administracion farmaceutica que contienen inhibidores de canales task-1 y task-3 y su uso para el tratamiento de trastornos respiratorios | |
| MX2024014626A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| WO2007133796A3 (en) | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist | |
| MXPA02012730A (es) | Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide. | |
| EA200700178A1 (ru) | Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения | |
| WO2016025671A3 (en) | Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist |